

and doxorubicin or paclitaxel and navelbine. Two weeks later accelerated radiotherapy was begun. The breast and internal mammary chain were irradiated with two tangential fields, nodes – with anterior irregular shaped field. Linear accelerator (6 MeV) was used to deliver 2 Gy per fraction, b.i.d., for 5 days/week up to a total dose of 44 Gy to breast and 40 Gy to regional lymphatic nodes. Radical mastectomy was performed after three-four weeks rest period.

Results: The overall objective preoperative response rate was 93.5%. When the postmastectomy histopathological examination was performed, there was no evidence of primary tumour in five (16%) cases. There were found only devitalized single tumour cells in 7 (22.5%) postmastectomy breasts, and another five specimens presented significant tumour destruction. In 12 (48%) patients of 25 with initially involved lymphatic areas, the nodes turned out to be morphologically intact. There were no serious reactions and toxicity during and after treatment. In 5 cases we observed delayed healing of postoperative wound. Indurative subcutaneous fibrosis occurred in 3 women. During the follow-up period there were 4 (12.9%) deaths due to disease progression.

Conclusion: Accelerated preoperative irradiation in combination with chemotherapy is effective treatment of breast cancer. Our technique allows performing mastectomy and adjuvant chemotherapy without a significant delay. Overall time of radiation treatment was only 15 days. This regimen proved to be safe with accepted toxicities. It seems to be reasonable not to replace preoperative irradiation by chemotherapy but to combine these treatment modalities.

473

PUBLICATION

High-dose chemotherapy and autologous peripheral blood stem cell transplantation in metastatic breast cancer. Updated results of a single center

K. Okan¹, S. Komurcu¹, F. Arpacı¹, A. Özet¹, M. Beyzadeoglu², C. Ulutin², S. Ataergin¹. ¹Gulhane School Of Medicine, Medical Oncology, Ankara, Turkey; ²Gulhane School Of Medicine, Radiation Oncology, Ankara, Turkey

Introduction: High-dose chemotherapy is not standard in the treatment of breast cancer, neither in the adjuvant nor in the metastatic setting. In this retrospective study, we aimed to review the interim data of metastatic breast cancer patients who underwent high-dose chemotherapy (HDC) and autologous peripheral blood stem cell transplantation (APBSCT) in our BMT center.

Material and methods: Between October 1984 and March 1997, 28 patients with metastatic breast cancer were treated with HDC and APBSCT. Their ages ranged from 23 to 63 years with a median age of 35 years. The time from diagnosis to transplant ranged from 109 to 2470 days with a median of 717 days. The number of their previous chemotherapy cycles ranged from 4 to 18 with a mean of 9. Their preparative regimens were: CNV (n = 19): Cyclophosphamide 2.4 g/m², mitoxantrone 35 mg/m², etoposide 250 mg/m²/d *6 days; ICE (n = 8): Ifosfamide 2.5 g/m²/d *6 days, carboplatin 250 mg/m²/d *6 days, etoposide 250 mg/m²/d *6 days; CNP (n = 1): Cyclophosphamide 60 mg/kg/d *2days, mitoxantrone 35 mg/m², carboplatin 200 mg/m²/d *6 days. In the posttransplant period, 20 patients received G-CSF (granulocyte colony stimulating factor), 6 patients GM-CSF (granulocyte-monocyte colony stimulating factor), and 2 patients received no GF.

Results: Recovery to $\geq 1 \times 10^9$ leukocyte/L occurred at a median of 11 days, platelet recovery to $\geq 20 \times 10^9/L$ was 13 days. A mean of 3.3 units of red cell suspensions and a mean of 2.8 units of platelet suspension were transfused. The mean hospitalization duration was 13 days. After median follow-up of 1010 days (range 3–2921 days), the survival probability at five years was calculated as 25%. The transplant related mortality was 10.3%.

Conclusion: The place of HDC in metastatic breast cancer is still controversial. Further randomized studies with more patients and longer follow-up are needed to clarify this issue.

474

PUBLICATION

Efficiency of Toremifen and Letrozol in the treatment of patients with advanced breast cancer

R. Zeynalov, I. Musayev, S. Gıyasbeyli, N. Dadasheva, J. Gasanzade, A. Yusifov, N. Ahadova. *Azerbaijan National Oncological Center, Baku, Azerbaijan*

Background: For the last years the discussion and researches about efficiency and sequence of use of antiestrogens and aromatase inhibitors in the treatment of advanced breast cancer have not been stopping. For many years antiestrogens (Tamoxifen and Toremifen) were considered standard medicines of first line in the treatment of postmenopausal women with advanced breast cancer. Last years results of researches which have demonstrated advantages aromatase inhibitor Letrozol over Tamoxifen

as first line therapy at the patients with advanced breast cancer were published. At the same time did not investigate comparative efficiency high doses of Toremifen and Letrozol. The aim of this trial is comparative study of Toremifen and Letrozol efficiency in the treatment of patients with advanced breast cancer.

Material and methods: 451 receptor statuses not considered patients with advanced breast cancer were involved in this clinical trial. Patient were divided on 4 groups/Hormonal therapy with Tamoxifen at a dose of 20 mg once daily was administered in 117 patients – I group, hormonal therapy with Toremifen at a dose of 60 mg once daily was administered in 115 patients – II group, 106 patients (III group) received Toremifen at a dose of 240 mg daily, 113 patients (IV group) were treated with Letrozol at a dose of 2.5 mg once daily. Patients continued on study medication until disease progression. Efficiency of treatment was determined with following criteria: objective effect, side effects and duration of remission.

Results: In the first group 30(25.6%) patients, in second group 38 (33.0%) patients, in the third group 44 (41.5%) patients, in the fourth group 40 (35.4%) had objective effect. Median remission time of 9.2; 11.3; 14.5 and 13.1 months. Side effects in all groups were not significant, did not require specific correction and delay of the treatment.

Conclusions: Our data indicated about advantages of Toremifen compared to Tamoxifen and comparable efficiency compared to Letrozol. On the base of the data we can recommend Toremifen for wide use as first line hormone therapy of patients with advanced breast cancer.

475

PUBLICATION

Clinical experience with trastuzumab in metastatic breast cancer

N. Sousa¹, N. Domingues¹, J.M. Maurício¹, M.J. Bento², J. Leal da Silva¹. ¹Instituto Português de Oncologia – Porto, *Oncologia Médica, Porto, Portugal*; ²Instituto Português de Oncologia – Porto, *Epidemiologia, Porto, Portugal*

Background: Trastuzumab (Tmab) is a monoclonal antibody used in the treatment of metastatic breast cancer (MBC) overexpressing c-erbB2 where it has been shown to improve time to progression, duration of response to chemotherapy and survival time.

Material and methods: We conducted a retrospective cohort analysis of patients (pts) with MBC overexpressing c-erbB2 (imunohistochemistry (IHC) 3+ score or positive FISH staining) treated with Tmab between Jun 2001 and Dec 2004 in Oporto's Instituto Português de Oncologia. Data was collected on demographics, tumour histology and stage, type and timing of all treatments offered as well as data on Tmab use. Outcome measures were time to progression (TtP) and survival after initiation of Tmab therapy. Statistical analysis was performed with SPSS 12.0.

Results: Fifty three pts were treated with Tmab. Their mean age at breast cancer (BC) diagnosis was 47.3 years (SD = 10). Initial stage grouping were: stage I in 6 pts, stage II in 10 pts, stage III in 30 pts and 7 had metastatic disease. Ductal invasive carcinoma was present in 49 (92.5%) pts, micropapillary carcinoma in 3 pts (5.7%) and 1 pts had carcinoma with no other specification. Positive estrogen receptor (ER) was present in 35 pts (67%) and 23 (44%) had positive progesterone receptor (PR). c-erbB2 overexpression was determined by IHC in 47 pts (89%) and by positive FISH in 6 pts (11%).

Radical mastectomy was the first treatment of 23 pts (43%), lumpectomy in 12 pts (24%) and chemotherapy was the initial treatment of 18 pts (33%). On the first relapse, 25 pts (48%) were treated with chemotherapy and Tmab was a first line palliative treatment in 19 pts (39%). Twenty-three patients developed minor side effects and only one patient had to stop Tmab because of cardiotoxicity.

Follow up was complete for all pts. Overall mortality was 46% (n = 23). The median survival time was 20 months. Survival was worse when pts had negative PR (p = 0.01 Log Rank [LR]) and age > 50 at BC diagnosis (p = 0.004 LR). The median TtP after initiation of Tmab was 10 months. PR negative pts (p = 0.045 LR), age at BC diagnosis > 50 (p = 0.004 LR) had a significative lower median TtP. We found no association between ER status or histologic grade and survival or TtP.

Conclusions: Tmab was an active and well tolerated drug in women with MBC and c-erbB2 overexpression. In our series PR status and younger age a BC diagnosis were surrogate markers of improved response to Tmab therapy.

476

PUBLICATION

Weekly Docetaxel seems to be as effective but better tolerated than 3 weeks Docetaxel

M. Draganescu, N. Gutulescu, D. Zob, A. Nita. *Oncological Institute of Bucharest, Medical oncology, Bucharest, Romania*

Considering the fact that weekly Paclitaxel was demonstrated to be as effective but less toxic than 3 weekly Paclitaxel, we evaluated the same